热门资讯> 正文
Trovagene up 48% on positive onvansertib data
2020-04-28 21:23
Thinly traded nano cap Trovagene (NASDAQ:TROV) jumps 48% premarket on robust volume in reaction to interim data from a Phase 1/2 clinical trial evaluating lead drug onvansertib, combined with chemo regimen FOLFIRI and Roche's Avastin (bevacizumab), for the second-line treatment of patients with KRAS mutation-positive metastatic colorectal cancer.
At data cutoff, 88% (n=7/8) of treated patients experienced at least stable cancer. Three patients responded, all partials.
Progression-free survival (median or mean not specified) is, so far, 6.5 months.
推荐文章
风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。
